Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Harnicar, A."'
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer Medicine, Vol 11, Iss 8, Pp 1796-1804 (2022)
Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several P
Externí odkaz:
https://doaj.org/article/6261ca0f91da4aafad9291fcc66547c9
Autor:
Griffin, Shawn P, Signorelli, Jessie R, Lasko, Aubrey, Andrick, Benjamin J, Doan, David, Hough, Shannon, Riebandt, Grazyna, Harnicar, Stephen
Publikováno v:
Journal of Oncology Pharmacy Practice; Mar2024, Vol. 30 Issue 2, p332-341, 10p
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 14, Pp 1247-1252 (2018)
Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memo
Externí odkaz:
https://doaj.org/article/cb08bd2484d44aab9d91ef3180fbed39
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Autor:
Laube, Eva S., Yu, Anthony, Gupta, Dipti, Miao, Yimei, Samedy, Patrick, Wills, Jonathan, Harnicar, Stephen, Soff, Gerald A., Mantha, Simon
Publikováno v:
In The American Journal of Cardiology 15 July 2017 120(2):213-217
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Harnicar, Stephen, Ponce, Doris M., Hilden, Patrick, Zheng, Junting, Devlin, Sean M., Lubin, Marissa, Pozotrigo, Melissa, Mathew, Sherry, Adel, Nelly, Kernan, Nancy A., O'Reilly, Richard, Prockop, Susan, Scaradavou, Andromachi, Hanash, Alan, Jenq, Robert, van den Brink, Marcel, Giralt, Sergio, Perales, Miguel A., Young, James W., Barker, Juliet N.
Publikováno v:
In Biology of Blood and Marrow Transplantation May 2015 21(5):920-925
Autor:
Griffin, Shawn P, Signorelli, Jessie R, Lasko, Aubrey, Andrick, Benjamin J, Doan, David, Hough, Shannon, Riebandt, Grazyna, Harnicar, Stephen
Supplemental material, sj-docx-1-opp-10.1177_10781552231174858 for Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey by Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c37302eed868b984d527e50376086aa
Autor:
Harnicar S, Mathew S
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 61-67 (2014)
Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML).
Externí odkaz:
https://doaj.org/article/86bb35367d5e4a31b6d06b29616cc28c
Autor:
Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, Stephen Harnicar
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311748
Introduction This study was designed to describe the landscape of oncology pharmacy practice at patient facing institutional healthcare organizations throughout the United States. Methods: The Hematology/Oncology Pharmacy Association (HOPA) Practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0facc77d2eb530b2b0cd94cd0166ec66
https://doi.org/10.1177/10781552231174858
https://doi.org/10.1177/10781552231174858
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer medicine. 11(8)
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on-target adverse effects (AEs) of PI3K/AKT inhibitors. As several PI3K and AKT inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0139831d25264fae3877890b57e59e3c
https://pubmed.ncbi.nlm.nih.gov/35212193
https://pubmed.ncbi.nlm.nih.gov/35212193